Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation

Detalhes bibliográficos
Autor(a) principal: Teixeira, Nádia Sofia Tavares
Data de Publicação: 2012
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.14/11528
Resumo: The global pharmaceutical industry is characterized for being highly competitive and for having though market regulations. Therefore, companies whose seek to generate value and continue with a strategic position in the market, look for different and smart ways to achieve the objective. In this industry, Mergers and Acquisitions are very supported by practitioners and managers, since it enhance the productivity of the company and the shareholder value. Merck & Co., Inc and Schering-Plough Corporation are an example of the merger of two companies that brought and incorporated different capabilities in an efficient way, therefore taking advantage of new opportunities in the different segments of the pharmaceutical industry. The goal of this dissertation is to do the historical financial analyze and estimate the enterprise value of both companies as if they were optimally managed; and assess the value of the merged entity and the synergies created. Last it is proposed an acquisition mode and optimal price for the deal to be accepted. Through the Literature Review it is presented explained the different valuation methods and M&A concepts and applications. This work showed that Merck & Co., Inc and Schering-Plough Corporation were undervalued during 2008, and the merger will create value of both companies. The estimated synergies, approximately $ 84 billion, represent 26 percent of the merged entity enterprise value. The company’s share price, by the end of 2008 was 30.4 and 17.03, Merck and Schering-Plough, respectively. As a result of all the valuation factors, the premium offered to Schering-Plough was 30 percent over the company’s average market capitalization, financed 51% with equity and the remaining with debt and cash.
id RCAP_3ae71c001871189cb04cd6b4ae2a3032
oai_identifier_str oai:repositorio.ucp.pt:10400.14/11528
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Mergers and acquisitions : the case of Merck & Co and Schering-Plough CorporationDomínio/Área Científica::Ciências Sociais::Economia e GestãoThe global pharmaceutical industry is characterized for being highly competitive and for having though market regulations. Therefore, companies whose seek to generate value and continue with a strategic position in the market, look for different and smart ways to achieve the objective. In this industry, Mergers and Acquisitions are very supported by practitioners and managers, since it enhance the productivity of the company and the shareholder value. Merck & Co., Inc and Schering-Plough Corporation are an example of the merger of two companies that brought and incorporated different capabilities in an efficient way, therefore taking advantage of new opportunities in the different segments of the pharmaceutical industry. The goal of this dissertation is to do the historical financial analyze and estimate the enterprise value of both companies as if they were optimally managed; and assess the value of the merged entity and the synergies created. Last it is proposed an acquisition mode and optimal price for the deal to be accepted. Through the Literature Review it is presented explained the different valuation methods and M&A concepts and applications. This work showed that Merck & Co., Inc and Schering-Plough Corporation were undervalued during 2008, and the merger will create value of both companies. The estimated synergies, approximately $ 84 billion, represent 26 percent of the merged entity enterprise value. The company’s share price, by the end of 2008 was 30.4 and 17.03, Merck and Schering-Plough, respectively. As a result of all the valuation factors, the premium offered to Schering-Plough was 30 percent over the company’s average market capitalization, financed 51% with equity and the remaining with debt and cash.Tsvetkov, PeterVeritati - Repositório Institucional da Universidade Católica PortuguesaTeixeira, Nádia Sofia Tavares2013-06-20T14:20:47Z2012-09-1120122012-09-11T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.14/11528enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-09-05T01:36:10Zoai:repositorio.ucp.pt:10400.14/11528Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:09:30.462651Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
title Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
spellingShingle Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
Teixeira, Nádia Sofia Tavares
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
title_short Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
title_full Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
title_fullStr Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
title_full_unstemmed Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
title_sort Mergers and acquisitions : the case of Merck & Co and Schering-Plough Corporation
author Teixeira, Nádia Sofia Tavares
author_facet Teixeira, Nádia Sofia Tavares
author_role author
dc.contributor.none.fl_str_mv Tsvetkov, Peter
Veritati - Repositório Institucional da Universidade Católica Portuguesa
dc.contributor.author.fl_str_mv Teixeira, Nádia Sofia Tavares
dc.subject.por.fl_str_mv Domínio/Área Científica::Ciências Sociais::Economia e Gestão
topic Domínio/Área Científica::Ciências Sociais::Economia e Gestão
description The global pharmaceutical industry is characterized for being highly competitive and for having though market regulations. Therefore, companies whose seek to generate value and continue with a strategic position in the market, look for different and smart ways to achieve the objective. In this industry, Mergers and Acquisitions are very supported by practitioners and managers, since it enhance the productivity of the company and the shareholder value. Merck & Co., Inc and Schering-Plough Corporation are an example of the merger of two companies that brought and incorporated different capabilities in an efficient way, therefore taking advantage of new opportunities in the different segments of the pharmaceutical industry. The goal of this dissertation is to do the historical financial analyze and estimate the enterprise value of both companies as if they were optimally managed; and assess the value of the merged entity and the synergies created. Last it is proposed an acquisition mode and optimal price for the deal to be accepted. Through the Literature Review it is presented explained the different valuation methods and M&A concepts and applications. This work showed that Merck & Co., Inc and Schering-Plough Corporation were undervalued during 2008, and the merger will create value of both companies. The estimated synergies, approximately $ 84 billion, represent 26 percent of the merged entity enterprise value. The company’s share price, by the end of 2008 was 30.4 and 17.03, Merck and Schering-Plough, respectively. As a result of all the valuation factors, the premium offered to Schering-Plough was 30 percent over the company’s average market capitalization, financed 51% with equity and the remaining with debt and cash.
publishDate 2012
dc.date.none.fl_str_mv 2012-09-11
2012
2012-09-11T00:00:00Z
2013-06-20T14:20:47Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.14/11528
url http://hdl.handle.net/10400.14/11528
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131767104339968